

**DISPENSING OF INTERCHANGEABLE BLOOD PRODUCTS**

NATIONAL  
111D00319

**REASON FOR ISSUE: Removal of MonoFIX®-VF which is no longer manufactured.**

Pharmacopoeia Title	Product Prescribed	Product Description	Current Position	Substitution	Informed Consent in event of Substitution
Antithrombin III	Thrombotrol®-VF	Antithrombin III Concentrate	Generally available	None required	None required
C1-Esterase Inhibitor	C1-Esterase Inhibitor	Berinert C1 Esterase inhibitor, human	Generally available. Section 29 Product	Substitute Berinert C1 Esterase inhibitor, human	None Required
	Berinert or Berinert P	Berinert C1 Esterase inhibitor, human	Only Berinert available Section 29 Product	No substitution	Not Applicable
Factor VIIa	Novoseven	Recombinant Coagulation Factor VIIa	Available	No substitution	Not Applicable
Factor VIII	Biostate	Biostate Injection with diluent	Available	No substitution	Prescription for Factor VIII must identify a specific product.
	Advate	Antihaemophilic Factor (Recombinant)	Available	No substitution	
	Kogenate FS	Factor VIII (rDNA)	Available	No substitution	
	Recombinate™	Antihaemophilic Factor (Recombinant)	Available	No substitution	Generic Prescriptions are not acceptable
	ReFacto®	Antihaemophilic Factor (Recombinant)	Available	No substitution	
Factor IX	Prothrombinex	Prothrombinex™-VF Human Prothrombin complex, powder for injection	Available	Patients receiving Prothombinex™-VF for the first time must be given information on product and storage conditions (1111123)	Prescription for Factor IX must identify a specific product.
	BeneFIX®	Coagulation Factor IX Recombinant	Available	No substitution	Generic prescriptions not acceptable
Fibrinogen Concentrate (Coagulation Factor 1)	RiaSTAP	Lyophilised plasma derived human fibrinogen	Available	No substitution	Not applicable

**DISPENSING OF INTERCHANGEABLE BLOOD PRODUCTS**

NATIONAL  
111D00319

<b>Pharmacopoeia Title</b>	<b>Product Prescribed</b>	<b>Product Description</b>	<b>Current Position</b>	<b>Substitution</b>	<b>Informed Consent in event of Substitution</b>
Hepatitis B Immunoglobulin, solution for intramuscular injection	Hepatitis B Immunoglobulin	Hepatitis B Immunoglobulin - VF	Potency of Hepatitis B Immunoglobulin -VF 400 IU from NZ plasma has fallen below specification	Substitute Hepatitis B Immunoglobulin –VF (Australian Plasma). Inform prescriber that it is a section 29 medicine	Patient must be informed when a substitution has been made
	HyperHEP B™ S/D	Hepatitis B Immune Globulin (Human)	Available, 110 IU dose only	No substitution	Not applicable
Human Anti-D (Rho) Immunoglobulin	Anti-D Immunoglobulin	Rh(D) Immunoglobulin-VF or Rhophylac	Available	Rh(D) Immunoglobulin-VF, & Rhophylac are forms of Anti-D Immunoglobulin. No substitution is involved but inform prescriber if a Section 29 product is provided.	Not Applicable
	Rh(D) Immunoglobulin-VF	Rh(D) Immunoglobulin-VF	Generally available	Substitute Rhophylac. Inform prescriber that it is a Section 29 medicine	Patient must be informed where a substitution has been made
	Rhophylac	Rhophylac (intravenous or intramuscular solution)	Available, 1500 IU dose Section 29 Product	No substitution	Not applicable
Human Immune Globulin for intravenous administration	Privigen®	Privigen® 10% Liquid	Access restricted requires TMS approval	Not permitted	Not applicable
Human Immune Globulin for subcutaneous administration	Hizentra®	Hizentra® Immune Globulin	Access restricted requires NMD approval Section 29 Product	No substitution	Not applicable
Human Normal Immunoglobulin, solution for intramuscular injection	Normal Immunoglobulin	Normal Immunoglobulin - VF	Generally available	Substitute Tetanus Immunoglobulin – VF (Australia). Inform prescriber that it is a Section 29 medicine	Patient must be informed where a substitution has been made
Human Normal Immunoglobulin for intravenous administration	Intragam® P	Intragam P Solution Normal Immunoglobulin (Human)	Generally available	Not permitted	Not Applicable
Human Normal Immunoglobulin for subcutaneous administration	Evogam®	Normal Immunoglobulin 16%w/v	Generally available	No substitution	None required

**DISPENSING OF INTERCHANGEABLE BLOOD PRODUCTS**

NATIONAL  
111D00319

<b>Pharmacopoeia Title</b>	<b>Product Prescribed</b>	<b>Product Description</b>	<b>Current Position</b>	<b>Substitution</b>	<b>Informed Consent in event of Substitution</b>
Human Rabies Immunoglobulin	Berirab P	Human rabies immunoglobulin	Limited supply of Imogam Rabies HT and Berirab P. Section 29 medicines	Either product can be dispensed	Patient must be informed when a substitution has been made
	Imogam Rabies HT				
Human Tetanus Immunoglobulin, solution for intramuscular injection	Tetanus Immunoglobulin	Tetanus Immunoglobulin - VF	Available	Substitute Tetanus Immunoglobulin – VF (Australia). Inform prescriber that it is a Section 29 medicine	Patient must be informed where a substitution has been made
Human Zoster Immunoglobulin, solution for intramuscular injection	Zoster Immunoglobulin	Zoster Immunoglobulin - VF	Restricted Supply. Requires approval by TMS	Substitute Zoster Immunoglobulin – VF (Australia). Inform prescriber that it is a Section 29 medicine	Patient must be informed where a substitution has been made